Tissue Repair (ASX:TRP) — Material Events
ASX:TRP · 5 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Tissue Repair Nears FDA Milestone with Strong Cash and Lower Manufacturing CostsMedium
Tissue Repair advances Phase III trial, targets FDA submission, reports strong cash and reduced manufacturing costs
31 July 2026
·Quarterly Cashflow Report and Operational Update
·85
Tissue Repair Seeks ASX Delisting with $1 Million Share Buy-Back OfferMedium
Tissue Repair Limited proposes ASX delisting with shareholder approval and share buy-back
23 July 2026
·Delisting Announcement
·75
Tissue Repair Eyes July Milestone as TR987 Trial Slows and TR Pro+ Sales PivotMedium
Tissue Repair updates slow Phase 3 trial progress, advances TR Pro+ commercialization and regulatory filings
30 Jan 2026
·Appendix 4C Quarterly Cash Flow Report
·75
No articles in this tier for the last 12 months.
Market Mentions
2
- appeared in market wrap coverage
These are market wrap articles where Tissue Repair (ASX:TRP) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026